These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11156221)

  • 21. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE
    Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of pioglitazone in Thai healthy subjects.
    Wittayalertpanya S; Chompootaweep S; Thaworn N
    J Med Assoc Thai; 2006 Dec; 89(12):2116-22. PubMed ID: 17214065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
    Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
    Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
    Ericsson H; Hamrén B; Bergstrand S; Elebring M; Fryklund L; Heijer M; Ohman KP
    Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
    Visser M; Holinka CF; Coelingh Bennink HJ
    Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Mistry GC; Luo WL; Liu Q; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman GA; Wagner JA; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):307-13. PubMed ID: 17571284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
    Ryan CW; Vogelzang NJ; Vokes EE; Kindler HL; Undevia SD; Humerickhouse R; André AK; Wang Q; Carr RA; Ratain MJ
    Clin Cancer Res; 2004 Jul; 10(13):4406-11. PubMed ID: 15240529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
    Muindi JR; Peng Y; Potter DM; Hershberger PA; Tauch JS; Capozzoli MJ; Egorin MJ; Johnson CS; Trump DL
    Clin Pharmacol Ther; 2002 Dec; 72(6):648-59. PubMed ID: 12496746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
    Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.
    Flory AB; Rassnick KM; Balkman CE; Kiselow MA; Autio K; Beaulieu BB; Lewis LD
    Am J Vet Res; 2008 Oct; 69(10):1316-22. PubMed ID: 18828689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous administration to rabbits.
    Han KS; Woo SJ; Koo CH; Lee MG
    Res Commun Mol Pathol Pharmacol; 1998 Apr; 100(1):29-34. PubMed ID: 9644716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.